Medannex Limited

Medannex Limited is a privately-owned, award-winning clinical-stage biopharmaceutical company based in Edinburgh, Scotland. It is dedicated to unlocking the therapeutic potential of targeting annexin-A1, a protein that drives cancer cell growth and migration and plays a key role in the development of several autoimmune conditions. The company's lead asset is MDX-124, described as the only therapeutic monoclonal antibody to target annexin-A1. Extensive pre-clinical data demonstrate that this first-in-class antibody effectively blocks the action of annexin-A1, and a Phase 1b clinical study is underway in cancer patients. In parallel, Medannex is preparing for further clinical studies in autoimmune diseases. Medannex was founded by serial life sciences entrepreneur Professor Chris Wood, who won the 'Lifetime Achievement Award' at Scotland's Life Sciences Annual Awards 2021. The company has established research collaborations with oncology and autoimmunity experts at leading institutions, including the University of Oxford, University of Glasgow, Mayo Clinic Arizona, University of Edinburgh, University of Liverpool, University College London, ARU Cambridge, Cardiff University, and Brighton & Sussex Medical School. It is a proud signatory of the Scottish Business Pledge, reflecting a commitment to sustainable growth, fairness, equality, opportunity, and innovation. Medannex operates in the biotechnology and pharmaceutical sector, focusing on first-in-class monoclonal antibody therapeutics. Its pipeline is centered on MDX-124, which is being evaluated in a first-in-human clinical study. The company has received recognition for its innovation, including a Scottish Life Sciences Innovation Award and a SMART grant to develop a 'biological missile' to tackle cancers. Medannex presents its clinical data at major conferences such as ESMO 2025 and the Cholangiocarcinoma Foundation's Annual Conference. As a privately-owned company, it remains active in advancing its clinical programs and expanding its research collaborations.

Medannex Limited was founded by Professor Chris Wood, a serial life sciences entrepreneur who was recognized with the 'Lifetime Achievement Award' at Scotland's Life Sciences Annual Awards 2021. The company is based in Edinburgh, Scotland, and operates as a privately-owned biopharmaceutical company. From its inception, Medannex has focused on targeting annexin-A1, a protein implicated in cancer, autoimmunity, and other diseases. The company's lead program, MDX-124, is described as the only therapeutic monoclonal antibody to target annexin-A1. Medannex has advanced MDX-124 into a first-in-human clinical study, specifically a Phase 1b trial in cancer patients. In parallel, the company is preparing for further clinical studies in autoimmune diseases. Medannex has built a network of research collaborations with oncology and autoimmunity experts at leading institutions, including the University of Oxford, University of Glasgow, Mayo Clinic Arizona, University of Edinburgh, University of Liverpool, University College London, ARU Cambridge, Cardiff University, and Brighton & Sussex Medical School. The company is a signatory of the Scottish Business Pledge and has received recognition such as the Scottish Life Sciences Innovation Award and a SMART grant. It continues to present clinical data at major conferences, including ESMO 2025 and the Cholangiocarcinoma Foundation's Annual Conference.

• 2026

  Medannex receives Scottish Life Sciences Innovation Award.

• 2026

  Medannex secures SMART grant to develop a 'biological missile' to tackle cancers.

• 2025

  Medannex unveils positive clinical data on MDX-124 at ESMO 2025.

• 2021

  Founder Professor Chris Wood receives Lifetime Achievement Award at Scotland's Life Sciences Annual Awards.

Clinical-stage biopharmaceutical company pioneering first-in-class monoclonal antibody therapeutics targeting annexin-A1 for cancers and autoimmune diseases.

• MDX-124

  First-in-class monoclonal antibody targeting annexin-A1; in Phase 1b clinical study for cancer.

1. 1Home page - Medannexmedannex.org
2. 2About - Medannexmedannex.org
3. 3Medannex Limited (United Kingdom) - Wikidatawikidata.org